StockNews.AI
INNPF
StockNews.AI
10 days

Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering

1. Innocan filed Form F-1 for a public offering in the U.S. 2. Units will include common shares and warrants for investors. 3. Common shares and warrants to be listed on Nasdaq as 'INNP' and 'INNPW'. 4. CEO expresses enthusiasm for new opportunities through Nasdaq listing. 5. Offering is subject to SEC review; no sales until registration is effective.

9m saved
Insight
Article

FAQ

Why Bullish?

The proposed public offering indicates financial confidence and potential growth. Historical examples indicate that similar offerings can lead to stock price increases.

How important is it?

The public offering and Nasdaq listing are significant milestones that can attract investors.

Why Short Term?

Immediate investor interest may lead to price changes as registration progresses. Past events show quick market reactions to similar announcements.

Related Companies

INNOIP4
, /PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed public offering of units (each, a "Unit" and collectively, the "Units") in the United States. Each Unit will be comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price and term in the context of the market. Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. ThinkEquity is acting as sole book-running manager for the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Iris Bincovich Innocan Pharma's CEO stated: "The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels." About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO15162104025++972-54-3012842+442037699377[email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer for Forward-Looking Information This press release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws and/or "forward-looking statements" within the meaning of applicable United States securities laws (collectively, "forward-looking statements"). Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: statements relating to the public offering of the Company's common shares; the expected timing of the public offering; the registration and listing of the Company's common shares in the United States; the registration statement becoming effective; the SEC's review process; the sizing and pricing of the offering; the means by which the offering will be made; and the Company's business strategies. Often, but not always, forward-looking statements may be identified by the use of words such as "expects", "anticipates", "plans", "projects", "estimates", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, the following estimates and assumptions: the Company carrying out its public offering; the Company successfully completing the SEC review process; obtaining requisite regulatory approvals; and general business, economic and market conditions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Important factors that may cause actual results to vary, include, without limitation, that the Company may not carry out its public offering or complete the SEC review process. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement or forward-looking information, except in accordance with applicable securities laws. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg SOURCE Innocan Pharma Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News